Overview

Resistance to Anti-CD20 Antibodies and Approaches for Their Reversal presents in-depth content written by international experts in the study of resistance to anti-CD20 antibodies and approaches for their reversal. Anti-CD20 antibodies are used to achieve B cell depletion and are developed to treat B cell proliferative disorders, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. In the past two decades, anti-CD20 antibodies have revolutionized the treatment of all B cell malignancies, however, there are patients that fail to respond to initial therapy or relapse sooner. This book explores new and existing avenues surrounding Anti-CD20 antibodies. In recent years, several next-generation anti-CD20 therapies have been developed but predicting and reversing resistance is still a challenging task. These areas are being actively studied as they represent a potential to improve anti-CD20 therapies and are discussed thoroughly in the book. It is a valuable resource for researchers, students and member of the biomedical and medical fields who want to learn more about resistance to anti-CD20 antibodies and their reversal.

Full Product Details

9780443192005

Table of Contents

Reviews

Author Information

William C.S. Cho, PhD, RCMP, FHKIMLS, FHKSMDS, Chartered Scientist (UK), FIBMS (UK). Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China. Dr. Cho’s primary research interests focus on cancer research to discover biomarkers for cancer diagnosis, treatment prediction, and prognosis. As a seasoned researcher, Dr. Cho has conducted cancer research using molecular biology, proteomics, genomics, immunology, bioinformatics, and next-generation sequencing technologies. Dr. Cho has published more than 600 peer-reviewed papers (Lancet, Lancet Oncology, Annals of Oncology, Lancet Gastroenterology & Hepatology, Advanced Science, Nature Communications, PNAS, Molecular Cancer, Journal of Thoracic Oncology, Journal of the National Cancer Institute, Journal of Extracellular Vesicles, Clinical Cancer Research, Clinical Chemistry, Theranostics, etc.) covering cancer biomarkers, proteomics, noncoding RNA, traditional Chinese medicine, and dozens of books (including An Omics Perspective on Cancer Research, MicroRNAs in Cancer Translational Research, Drug Repurposing in Cancer Therapy: Approaches and Applications, Supportive Cancer Care with Chinese Medicine, etc.). The cumulative impact factor of journals exceeds 4500, and the papers have been cited >25,000 times. Dr. Cho is listed among the top 2% of the most influential scientists in the world. In addition, Dr. Cho has served as a research grant reviewer for many international research funds, including the Hope Funds for Cancer Research (United States), Cancer Research (United Kingdom), National Medical Research Council (Singapore), etc.

Tab Content 6

Customer Reviews

Recent Reviews

Countries Available